These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37046852)

  • 1. Arginase Inhibition Mitigates Bortezomib-Exacerbated Cardiotoxicity in Multiple Myeloma.
    Paterek A; Oknińska M; Pilch Z; Sosnowska A; Ramji K; Mackiewicz U; Golab J; Nowis D; Mączewski M
    Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity.
    Ramji K; Grzywa TM; Sosnowska A; Paterek A; Okninska M; Pilch Z; Barankiewicz J; Garbicz F; Borg K; Bany-Laszewicz U; Zerrouqi A; Pyrzynska B; Rodziewicz-Lurzynska A; Papiernik D; Sklepkiewicz P; Kedzierska H; Staruch A; Sadowski R; Ciepiela O; Lech-Maranda E; Juszczynski P; Mackiewicz U; Maczewski M; Nowis D; Golab J
    Sci Rep; 2022 Nov; 12(1):19660. PubMed ID: 36385153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity.
    Heitner SB; Minnier J; Naher A; Van Woerkom RC; Ritts A; Ferencik M; Broberg C; Medvedova E; Silbermann R; Scott EC
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):796-802. PubMed ID: 30217616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy.
    Meseeha MG; Kolade VO; Attia MN
    J Community Hosp Intern Med Perspect; 2015; 5(6):28982. PubMed ID: 26653686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
    Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
    High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymmetric dimethylarginine (ADMA) elevation and arginase up-regulation contribute to endothelial dysfunction related to insulin resistance in rats and morbidly obese humans.
    El Assar M; Angulo J; Santos-Ruiz M; Ruiz de Adana JC; Pindado ML; Sánchez-Ferrer A; Hernández A; Rodríguez-Mañas L
    J Physiol; 2016 Jun; 594(11):3045-60. PubMed ID: 26840628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arginase Inhibition Restores Peroxynitrite-Induced Endothelial Dysfunction via L-Arginine-Dependent Endothelial Nitric Oxide Synthase Phosphorylation.
    Nguyen MC; Park JT; Jeon YG; Jeon BH; Hoe KL; Kim YM; Lim HK; Ryoo S
    Yonsei Med J; 2016 Nov; 57(6):1329-38. PubMed ID: 27593859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arginase Inhibition Improves Microvascular Endothelial Function in Patients With Type 2 Diabetes Mellitus.
    Kövamees O; Shemyakin A; Checa A; Wheelock CE; Lundberg JO; Östenson CG; Pernow J
    J Clin Endocrinol Metab; 2016 Nov; 101(11):3952-3958. PubMed ID: 27399350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between Markers of the Acute Phase of Inflammation, Parameters of Blood Lipid Composition and Intracardiac Hemodynamics During Chemotherapy in Patients With Multiple Myeloma.
    Kardanova SA; Kirichenko YY; Bochkarnikova OV; Antyufeeva ON; Kochkareva YB; Vinogradova OY; Privalova EV; Ilgisonis IS; Belenkov YN
    Kardiologiia; 2022 Sep; 62(9):18-26. PubMed ID: 36206134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus.
    Shemyakin A; Kövamees O; Rafnsson A; Böhm F; Svenarud P; Settergren M; Jung C; Pernow J
    Circulation; 2012 Dec; 126(25):2943-50. PubMed ID: 23183942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.
    Romano A; Parrinello NL; La Cava P; Tibullo D; Giallongo C; Camiolo G; Puglisi F; Parisi M; Pirosa MC; Martino E; Conticello C; Palumbo GA; Di Raimondo F
    Expert Rev Mol Diagn; 2018 Jul; 18(7):675-683. PubMed ID: 29707981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
    Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
    Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arginase Inhibition Reverses Endothelial Dysfunction, Pulmonary Hypertension, and Vascular Stiffness in Transgenic Sickle Cell Mice.
    Steppan J; Tran HT; Bead VR; Oh YJ; Sikka G; Bivalacqua TJ; Burnett AL; Berkowitz DE; Santhanam L
    Anesth Analg; 2016 Sep; 123(3):652-8. PubMed ID: 27537757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red blood cells from patients with pre-eclampsia induce endothelial dysfunction.
    McCann Haworth SM; Zhuge Z; Nihlén C; Von Rosen MF; Weitzberg E; Lundberg JO; Krmar RT; Nasiell J; Carlström M
    J Hypertens; 2021 Aug; 39(8):1628-1641. PubMed ID: 33657586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arginase inhibition augments nitric oxide production and facilitates left ventricular systolic function in doxorubicin-induced cardiomyopathy in mice.
    Toya T; Hakuno D; Shiraishi Y; Kujiraoka T; Adachi T
    Physiol Rep; 2014 Sep; 2(9):. PubMed ID: 25263201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management.
    Wu P; Oren O; Gertz MA; Yang EH
    Curr Oncol Rep; 2020 Jun; 22(7):66. PubMed ID: 32514632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased inducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S-nitrosylation.
    Heusch P; Aker S; Boengler K; Deindl E; van de Sand A; Klein K; Rassaf T; Konietzka I; Sewell A; Menazza S; Canton M; Heusch G; Di Lisa F; Schulz R
    Am J Physiol Heart Circ Physiol; 2010 Aug; 299(2):H446-53. PubMed ID: 20511413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity.
    Diwadkar S; Patel AA; Fradley MG
    Case Rep Cardiol; 2016; 2016():3456287. PubMed ID: 26942019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired L-arginine uptake but not arginase contributes to endothelial dysfunction in rats with chronic kidney disease.
    Martens CR; Kuczmarski JM; Lennon-Edwards S; Edwards DG
    J Cardiovasc Pharmacol; 2014 Jan; 63(1):40-8. PubMed ID: 24084210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase.
    Hein TW; Zhang C; Wang W; Chang CI; Thengchaisri N; Kuo L
    FASEB J; 2003 Dec; 17(15):2328-30. PubMed ID: 14563685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.